Amgen Inc (AMGN)
308.45
-1.70
(-0.55%)
USD |
NASDAQ |
May 13, 16:00
307.00
-1.45
(-0.47%)
After-Hours: 20:00
Amgen Enterprise Value: 220.69B for May 10, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 10, 2024 | 220.69B |
| May 09, 2024 | 222.14B |
| May 08, 2024 | 219.16B |
| May 07, 2024 | 215.40B |
| May 06, 2024 | 214.96B |
| May 03, 2024 | 221.30B |
| May 02, 2024 | 203.65B |
| May 01, 2024 | 203.10B |
| April 30, 2024 | 201.26B |
| April 29, 2024 | 202.57B |
| April 26, 2024 | 199.12B |
| April 25, 2024 | 198.80B |
| April 24, 2024 | 200.75B |
| April 23, 2024 | 201.03B |
| April 22, 2024 | 200.16B |
| April 19, 2024 | 198.56B |
| April 18, 2024 | 195.24B |
| April 17, 2024 | 195.95B |
| April 16, 2024 | 196.79B |
| April 15, 2024 | 196.73B |
| April 12, 2024 | 197.67B |
| April 11, 2024 | 199.13B |
| April 10, 2024 | 197.23B |
| April 09, 2024 | 199.33B |
| April 08, 2024 | 198.70B |
| Date | Value |
|---|---|
| April 05, 2024 | 199.11B |
| April 04, 2024 | 198.11B |
| April 03, 2024 | 201.50B |
| April 02, 2024 | 202.46B |
| April 01, 2024 | 206.13B |
| March 31, 2024 | 206.68B |
| March 28, 2024 | 206.04B |
| March 27, 2024 | 207.10B |
| March 26, 2024 | 204.67B |
| March 25, 2024 | 204.17B |
| March 22, 2024 | 201.67B |
| March 21, 2024 | 202.09B |
| March 20, 2024 | 200.00B |
| March 19, 2024 | 199.29B |
| March 18, 2024 | 198.85B |
| March 15, 2024 | 197.76B |
| March 14, 2024 | 199.19B |
| March 13, 2024 | 201.58B |
| March 12, 2024 | 201.87B |
| March 11, 2024 | 201.24B |
| March 08, 2024 | 200.38B |
| March 07, 2024 | 199.90B |
| March 06, 2024 | 201.90B |
| March 05, 2024 | 201.93B |
| March 04, 2024 | 203.40B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
108.40B
Minimum
May 31 2019
227.44B
Maximum
Feb 01 2024
158.68B
Average
158.74B
Median
Nov 09 2020
Enterprise Value Benchmarks
| Johnson & Johnson | 368.20B |
| Eli Lilly and Co | 746.02B |
| Merck & Co Inc | 358.08B |
| Pfizer Inc | 215.78B |
| Vertex Pharmaceuticals Inc | 98.93B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -113.00M |
| Revenue (Quarterly) | 7.447B |
| Total Expenses (Quarterly) | 6.456B |
| EPS Diluted (Quarterly) | -0.21 |
| Gross Profit Margin (Quarterly) | 57.03% |
| Profit Margin (Quarterly) | -1.52% |
| Earnings Yield | 2.27% |
| Operating Earnings Yield | 4.21% |
| Normalized Earnings Yield | 2.270 |